Linkedin-in

Delphi Diagnostics Announces New Publication Confirming EAI Predicts Benefit from Weekly Paclitaxel in HR+/HER2− Breast Cancer

Press Release Delphi Diagnostics Announces New Publication Confirming EAI Predicts Benefit from Weekly Paclitaxel in HR+/HER2− Breast Cancer This analysis independently validated previous findings and further helps to establish EAI as the first genomic assay shown to predict benefit from a contemporary taxane-based chemotherapy regimen in HR+/HER2− breast cancer. A PDF of the release can […]

Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer

Press Release Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer Experienced oncology and life sciences executive to lead financial strategy and support the next phase of growth A PDF of the release can be found here May 19, 2026, Houston, TX  – Delphi Diagnostics today announced the appointment of Eric Lindquist as Chief Financial […]

Delphi Diagnostics Announces New Publication in the European Journal of Cancer

Press Release Delphi Diagnostics Announces New Publication in the European Journal of Cancer Peer-reviewed manuscript demonstrates the Endocrine Activity IndexTM Recurrence Risk (EAIRR) enhances risk stratification beyond Recurrence Score® and is predictive of endocrine therapy benefit A PDF of the release can be found here Houston, TX, May 6, 2026 — Delphi Diagnostics today announced the publication […]

Delphi Diagnostics Appoints Harry Bushong to Board of Directors

Press Release Delphi Diagnostics Appoints Harry Bushong to Board of Directors A PDF of the release can be found here Seasoned venture capital leader brings deep expertise in life sciences and healthcare innovation Houston, TX, April 6, 2026 — Delphi Diagnostics today announced the appointment of Harry Bushong to its Board of Directors. A veteran […]

Data Presented at SABCS 2025 Demonstrated that the Endocrine Activity Index® (EAI®) May Identify Patients Most Likely to Benefit from Extended Endocrine Therapy

Press Release Data Presented at SABCS 2025 Demonstrated that the Endocrine Activity Index® (EAI®) May Identify Patients Most Likely to Benefit from Extended Endocrine Therapy A PDF of the release can be found here Houston, TX, February 16, 2026 — New data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) from the NRG/NSABP […]

Data Presented at SABCS 2025 Reinforce the Endocrine Activity Index® (EAI®) as a Powerful Tool to Inform Treatment Decisions in HR+/HER2- Breast Cancer

Press Release Data Presented at SABCS 2025 Reinforce the Endocrine Activity Index® (EAI®) as a Powerful Tool to Inform Treatment Decisions in HR+/HER2- Breast Cancer A PDF of the release can be found here Houston, TX, February 10, 2026 – Delphi Diagnostics today announced that clinical evidence presented at the 2025 San Antonio Breast Cancer […]

Delphi Diagnostics® Announces Four Abstracts and one General Session Presentation Featuring the Endocrine Activity IndexTM to be Presented at the San Antonio Breast Cancer Symposium

Press Release Delphi Diagnostics® Announces Four Abstracts and one General Session Presentation Featuring the Endocrine Activity Index® to be Presented at the San Antonio Breast Cancer Symposium A PDF of the release can be found here Houston, TX, November 4, 2025 – Delphi Diagnostics announces the upcoming presentation of four scientific abstracts, including one platform […]

Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™

Press Release Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™ Houston, TX, October 27, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 […]

SET2,3TM index adds independent, complementary information to personalize breast cancer treatment

Press Release SET2,3™ Index Adds Independent, Complementary Information to Personalize Breast Cancer Treatment December 14, 2021 – Delphi Diagnostics Inc. is pleased to announce that its SET2,3 index, a standard measure of gene expression known as the Sensitivity-to-Endocrine-Therapy, was found to have prognostic value that complements the known prognostic value of the 21-gene Oncotype DX […]